The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma-unveiling the future challenges in drug therapy  

作　　者：Naoshi Nishida 

机构地区：[1]Department of Gastroenterology and Hepatology,Kindai University Faculty of Medicine,Osaka-Sayama,Japan

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第5期790-794,共5页肝胆外科与营养（英文）

基　　金：supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science(KAKENHI:21K07184);a grant from Smoking Research Foundation.

摘　　要：Intrahepatic cholangiocarcinoma(iCCA)is a rare malignancy,constituting approximately 3-5%of hepatic tumors,with an increasing incidence in recent years(1).Early stage iCCA typically presents asymptomatically,often resulting in its detection at advanced stages.Surgical resection remains the primary therapeutic approach for iCCA;however,a substantial proportion of patients are precluded from surgery due to disease progression,necessitating a reliance on pharmaceutical interventions(2).

关 键 词：Intrahepatic cholangiocarcinoma(iCCA) fibroblast growth factor receptor inhibitor(FGFR inhibitor) MUTATION CHEMOTHERAPY tumor immune microenvironment(TIME) 

分 类 号：R735.8[医药卫生—肿瘤]